Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research

Q&A with FDA Podcast: The Current Status of Oral Phenylephrine as a Nasal Decongestant with Dr. Theresa Michele and Dr. Ilisa Bernstein

Enroll
Step Status
Educational Content ✘
Posttest ✘
Evaluation ✘
Starts On: Tue, 3/19/24: 12:00 AM EDT
Ends On: Thu, 3/18/27: 12:00 AM EDT
Type: Enduring Material
Credits: 0.5
Description: This enduring material focuses on the results of a recent FDA advisory committee meeting on the effectiveness of oral epinephrine as a nasal decongestant. The presenters provide background on why the meeting was convened, clarify the results of the meeting, and discuss next steps. In addition, the presenters have an open dialogue discussing pharmacists' perceptions and role in educating the public on the topic.
Objectives:
  • Describe the next steps that would occur if FDA determines that oral phenylephrine is not generally recognized as safe and effective (“GRASE”) as an OTC nasal decongestant.
  • Summarize the results of the FDA Nonprescription Drugs Advisory Committee meeting convened on September 11-12, 2023, discussing the new data regarding oral phenylephrine’s effectiveness as a nasal decongestant.
  • Discuss the implications of the advisory committee on the pharmacist’s role in educating consumers about oral phenylephrine and the selection of cough-cold over-the-counter (OTC) products.
Additional Information: Review the Activity Announcement for additional details: Announcement Form